Trials / Recruiting
RecruitingNCT07082738
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
A Multicentre, Parallel-group, Phase IIb, Randomised, Double-blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1,160 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
This Phase IIb dose-ranging study will evaluate the efficacy and safety of 3 different doses of AZD6793 compared with placebo tablets in participants with moderate to very severe chronic obstructive pulmonary disease.
Detailed description
A Multicentre, Parallel-group, Phase IIb, Randomised, Double-blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO) Approximately 400 sites globally will participate in this study. Approximately 1160 participants will be randomized to four treatment groups; three different doses of AZD6793 vs placebo in a 1:1:1:1 ratio.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD6793 | Oral dosage |
| OTHER | Placebo | Oral dosage |
Timeline
- Start date
- 2025-06-27
- Primary completion
- 2027-11-05
- Completion
- 2027-11-05
- First posted
- 2025-07-24
- Last updated
- 2026-03-17
Locations
363 sites across 24 countries: United States, Argentina, Australia, Bulgaria, Canada, Chile, China, Denmark, Germany, Greece, Hungary, India, Italy, Japan, Mexico, Peru, Poland, South Korea, Spain, Taiwan, Turkey (Türkiye), Ukraine, United Kingdom, Vietnam
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07082738. Inclusion in this directory is not an endorsement.